As of 2025-03-21, the Relative Valuation of C4 Therapeutics Inc (CCCC) is (56.37) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.19 USD, the upside of C4 Therapeutics Inc based on Relative Valuation is -2674.2%.
The range of the Relative Valuation is (46.58) - (72.99) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.4x - 49.2x | 41.4x |
| Forward P/E multiples | 26.9x - 50.1x | 34.6x |
| Fair Price | (46.58) - (72.99) | (56.37) |
| Upside | -2227.1% - -3432.9% | -2674.2% |
| Date | P/E |
| 2025-03-18 | -1.40 |
| 2025-03-17 | -1.41 |
| 2025-03-14 | -1.37 |
| 2025-03-13 | -1.36 |
| 2025-03-12 | -1.48 |
| 2025-03-11 | -1.38 |
| 2025-03-10 | -1.46 |
| 2025-03-07 | -1.59 |
| 2025-03-06 | -1.59 |
| 2025-03-05 | -1.64 |
| 2025-03-04 | -1.60 |
| 2025-03-03 | -1.62 |
| 2025-02-28 | -1.83 |
| 2025-02-27 | -1.75 |
| 2025-02-26 | -1.79 |
| 2025-02-25 | -1.88 |
| 2025-02-24 | -1.95 |
| 2025-02-21 | -2.03 |
| 2025-02-20 | -2.02 |
| 2025-02-19 | -2.03 |
| 2025-02-18 | -2.00 |
| 2025-02-14 | -2.14 |
| 2025-02-13 | -2.16 |
| 2025-02-12 | -2.22 |
| 2025-02-11 | -2.20 |
| 2025-02-10 | -2.27 |
| 2025-02-07 | -2.39 |
| 2025-02-06 | -2.41 |
| 2025-02-05 | -2.46 |
| 2025-02-04 | -2.29 |
| 2025-02-03 | -2.26 |
| 2025-01-31 | -2.34 |
| 2025-01-30 | -2.48 |
| 2025-01-29 | -2.42 |
| 2025-01-28 | -2.45 |
| 2025-01-27 | -2.44 |
| 2025-01-24 | -2.45 |
| 2025-01-23 | -2.52 |
| 2025-01-22 | -2.50 |
| 2025-01-21 | -2.60 |
| 2025-01-17 | -2.66 |
| 2025-01-16 | -2.60 |
| 2025-01-15 | -2.72 |
| 2025-01-14 | -2.52 |
| 2025-01-13 | -2.36 |
| 2025-01-10 | -2.47 |
| 2025-01-08 | -2.59 |
| 2025-01-07 | -2.60 |
| 2025-01-06 | -2.76 |
| 2025-01-03 | -2.64 |